Details for Patent: 9,675,587

Which drugs does patent 9,675,587 protect, and when does it expire?

Patent 9,675,587 protects VIBERZI and is included in one NDA.

This patent has thirty patent family members in twenty countries.

Summary for Patent: 9,675,587

Title:	Opioid receptor modulator dosage formulations
Abstract:	Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Inventor(s):	Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
Assignee:	Allergan Holdings ULC
Application Number:	US13/829,984
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,675,587
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,675,587

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	9,675,587		Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	9,675,587		Y

International Family Members for US Patent 9,675,587

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014241076
Brazil	112015022753
Canada	2906472
China	105228629
China	110917159
Cyprus	1120892